Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE For The Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes; Under The Terms Of The Licensing Agreement With Merck, Ligand Earned A $2M Milestone Payment

By Benzinga Newsdesk
Today, 8:33 AM
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCETM, also known as V114, for the prevention of

LGND

Read More
3 minute read

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs

By Shanthi Rexaline
Today, 8:33 AM
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks. There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.

ABT

Read More
1 minute read
Uncategorized

Recap: Ligand Pharmaceuticals Q1 Earnings

By Benzinga Insights
Today, 8:33 AM
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) fell 7% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.43% over the past year to $1.41, which beat the estimate of $1.12.

LGND